Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

Blood (2023) 141 (9): 1023–1035.

https://doi.org/10.1182/blood.2021015246

Published: 2023

Includes: Supplemental data

Journal Articles

Tyrosin Kinase Inhibition Restores the Membrane Localization of FLT3-ITD

Katrin S. Reiter, Harald Polzer, PhD, Christina Krupka, Binje Vick, PhD, Andreas Maiser, Marion S. Subklewe, MD, Irmela Jeremias, MD, Heinrich Leonhardt, PhD, Karsten Spiekermann, MD, Philipp A. Greif, MD

Blood (2015) 126 (23): 1274.

https://doi.org/10.1182/blood.V126.23.1274.1274

Published: 2015

Journal Articles

Activating FLT3 Mutations Display a Wide Range Of Transforming Potential and a Characteristic Pathway Profile Associated With Prognosis In Acute Myeloid Leukemia

Hanna Janke, Friederike Schneider, MD, Daniela Schumacher, Tobias Herold, MD, Hopfner Karl-Peter, PhD, Stephanie Schneider, PhD, Wolfgang E. Berdel, MD, Thomas Büchner, MD, Bernhard J. Woermann, MD, Marion Subklewe, MD, Stefan K. Bohlander, MD, Wolfgang Hiddemann, MD, Harald Polzer, PhD, Karsten Spiekermann, MD

Blood (2013) 122 (21): 1312.

https://doi.org/10.1182/blood.V122.21.1312.1312

Published: 2013

Journal Articles

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Blood (2013) 122 (10): 1761–1769.

https://doi.org/10.1182/blood-2013-01-476473

Published: 2013

Includes: Supplemental data

Journal Articles

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

Sabrina Opatz, Harald Polzer, Tobias Herold, MD, Nikola P Konstandin, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Karl Peter Hopfner, PhD, Purvi M. Kakadia, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Jan Braess, MD, Michael Heuser, MD, Wolfgang Hiddemann, MD, PhD, Karsten Spiekermann, MD, Stefan K Bohlander, MD, Philipp A Greif, MD

Blood (2012) 120 (21): 404.

https://doi.org/10.1182/blood.V120.21.404.404

Published: 2012

Journal Articles

CBL Deletion Mutant Found in AML Patients Cause Transformation of Receptor Tyrosine Kinase Class III Expressing Cells by Activation of the AKT Pathway

Harald Polzer, Hanna Janke, Wolfgang Hiddemann, MD, Dirk Eick, Ph.D., Karsten Spiekermann, MD

Blood (2011) 118 (21): 2447.

https://doi.org/10.1182/blood.V118.21.2447.2447

Published: 2011

NARROW

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

Tyrosin Kinase Inhibition Restores the Membrane Localization of FLT3-ITD

Activating FLT3 Mutations Display a Wide Range Of Transforming Potential and a Characteristic Pathway Profile Associated With Prognosis In Acute Myeloid Leukemia

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

CBL Deletion Mutant Found in AML Patients Cause Transformation of Receptor Tyrosine Kinase Class III Expressing Cells by Activation of the AKT Pathway

Email alerts

ASH Publications

American Society of Hematology

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

Tyrosin Kinase Inhibition Restores the Membrane Localization of FLT3-ITD

Activating FLT3 Mutations Display a Wide Range Of Transforming Potential and a Characteristic Pathway Profile Associated With Prognosis In Acute Myeloid Leukemia

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

CBL Deletion Mutant Found in AML Patients Cause Transformation of Receptor Tyrosine Kinase Class III Expressing Cells by Activation of the AKT Pathway

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only